Avoro Capital Advisors LLC - Q4 2016 holdings

$495 Million is the total value of Avoro Capital Advisors LLC's 44 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 48.0% .

 Value Shares↓ Weighting
BMRN SellBIOMARIN PHARMACEUTICAL INC$33,136,000
-14.7%
400,000
-4.7%
6.69%
-1.8%
TSRO SellTESARO INC$31,159,000
+11.9%
231,700
-16.6%
6.30%
+28.9%
SRPT SellSAREPTA THERAPEUTICS INC$27,713,000
-67.1%
1,010,300
-26.3%
5.60%
-62.1%
DERM SellDERMIRA INC$23,224,000
-14.8%
765,709
-5.0%
4.69%
-1.9%
BMY SellBRISTOL MYERS SQUIBB CO.$16,655,000
-22.8%
285,000
-28.7%
3.36%
-11.0%
AKBA SellAKEBIA THERAPEUTICS INC$8,656,000
+1.3%
831,515
-12.0%
1.75%
+16.6%
SRNE SellSORRENTO THERAPEUTICS INC$7,135,000
-39.8%
1,456,056
-4.9%
1.44%
-30.7%
VCYT SellVERACYTE INC$7,020,000
+0.4%
906,999
-1.3%
1.42%
+15.6%
VNDA SellVANDA PHARMACEUTICALS INC$6,084,000
-55.8%
381,466
-53.9%
1.23%
-49.2%
FBIO SellFORTRESS BIOTECH INC$3,241,000
-19.6%
1,200,342
-11.5%
0.66%
-7.4%
CRVS SellCORVUS PHARMACEUTICALS INC$3,098,000
-29.8%
216,619
-19.3%
0.63%
-19.2%
SellPERNIX THERAPEUTICS HOLDINGS INCconvertible debt$1,479,000
-27.9%
6,000,000
-14.3%
0.30%
-16.9%
SellTRILLIUM THERAPEUTICS INC$1,285,000
-72.5%
227,399
-28.0%
0.26%
-68.3%
DRNA ExitDICERNA PHARMACEUTICALS INC$0-46,082
-100.0%
-0.05%
NK ExitNANTKWEST INC$0-72,412
-100.0%
-0.10%
VCEL ExitVERICEL CORP$0-215,744
-100.0%
-0.11%
CEMP ExitCEMPRA INC$0-30,000
-100.0%
-0.13%
OMED ExitONCOMED PHARMACEUTICALS INC$0-85,000
-100.0%
-0.17%
VSAR ExitVERSARTIS INC$0-95,742
-100.0%
-0.21%
INNL ExitINNOCOLL HOLDINGS PLCshares$0-468,148
-100.0%
-0.48%
PTI ExitPROTEOSTASIS THERAPEUTICS INC$0-179,565
-100.0%
-0.49%
SRPT ExitSAREPTA THERAPUTICS INCcall$0-190,000
-100.0%
-1.06%
AGIO ExitAGIOS PHARMACEUTICALS INC$0-150,000
-100.0%
-1.39%
CASC ExitCASCADIAN THERAPEUTICS INC$0-5,611,323
-100.0%
-1.62%
GWPH ExitGW PHARMACEUTICALS PLCads$0-133,600
-100.0%
-3.11%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2017-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AMICUS THERAPEUTICS INC36Q3 202317.9%
MIRATI THERAPEUTICS INC.35Q3 202317.2%
BIOMARIN PHARMACEUTICAL INC31Q3 20238.0%
SAREPTA THERAPUTICS INC28Q3 202314.8%
ASCENDIS PHARMA28Q3 20239.1%
ARGENX SE26Q3 20239.5%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%
FENNEC PHARMACEUTICALS INC25Q3 20230.4%
MADRIGAL PHARMACEUTICALS INC22Q3 20237.2%
XENON PHARMACEUTICALS INC22Q3 20233.3%

View Avoro Capital Advisors LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Avoro Capital Advisors LLC Q4 2016 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Adverum Biotechnologies, Inc.Sold outFebruary 14, 202300.0%
DICE Therapeutics, Inc.February 14, 20232,525,5555.3%
IOVANCE BIOTHERAPEUTICS, INC.February 14, 20237,020,0004.4%
IVERIC bio, Inc.February 14, 20236,750,0005.0%
Kura Oncology, Inc.February 14, 20233,105,0004.5%
Aadi Bioscience, Inc.September 26, 20222,849,40211.7%
ARENA PHARMACEUTICALS INCFebruary 11, 20221,235,0002.0%
AVADEL PHARMACEUTICALS PLCFebruary 11, 20221,670,0002.9%
FENNEC PHARMACEUTICALS INC.February 11, 20221,200,0004.6%
POINT Biopharma Global Inc.Sold outFebruary 11, 202200.0%

View Avoro Capital Advisors LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
SC 13G/A2024-04-23
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Avoro Capital Advisors LLC's complete filings history.

Compare quarters

Export Avoro Capital Advisors LLC's holdings